Trimetrexate

Trimetrexate
Systematic (IUPAC) name

5-methyl-6-[(3,4,5-trimethoxyphenyl) aminomethyl] quinazoline-2,4-diamine
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a694019
Pharmacokinetic data
Bioavailability	VD: 20-30 Liters
Metabolism	Oxidative O-demethylation, followed by conjugation with glucuronide or sulfate
Biological half-life	11 to 12 hours
Identifiers
CAS Number	52128-35-5^Y
ATC code	P01AX07 (WHO)
PubChem	CID 5583
IUPHAR/BPS	7613
DrugBank	DB01157^Y
ChemSpider	5381^Y
UNII	UPN4ITI8T4^Y
KEGG	D06238^Y
ChEMBL	CHEMBL119^Y
Chemical data
Formula	C₁₉H₂₃N₅O₃
Molar mass	369.418 g/mol
SMILES n3c1c(c(c(cc1)CNc2cc(OC)c(OC)c(OC)c2)C)c(nc3N)N
InChI InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)^Y Key:NOYPYLRCIDNJJB-UHFFFAOYSA-N^Y
(verify)

Trimetrexate is a quinazoline derivative. It is a dihydrofolate reductase inhibitor.^[1]

Uses

It has been used with leucovorin in treating pneumocystis pneumonia.^[2]

It has been investigated for use in treating leiomyosarcoma.^[3] It is a methotrexate (MTX) analog that is active against transport-deficient MTX-resistant tumor cells that overcome the acquired and natural resistance to methotrexate. Other uses include skin lymphoma. ^[4]

References

↑ Wong BK, Woolf TF, Chang T, Whitfield LR (1990). "Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog". Drug Metab. Dispos. 18 (6): 980–6. PMID 1981548.
↑ Sattler FR, Allegra CJ, Verdegem TD, et al. (January 1990). "Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia". J. Infect. Dis. 161 (1): 91–6. doi:10.1093/infdis/161.1.91. PMID 2136905.
↑ Smith HO, Blessing JA, Vaccarello L (January 2002). "Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group". Gynecol. Oncol. 84 (1): 140–4. doi:10.1006/gyno.2001.6482. PMID 11748990.
↑ Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol. 2002 Jun 15;20(12):2876-80.

External links

MedlinePlus DrugInfo uspdi-202693
DDB 30480

Antiparasitics – antiprotozoal agents – Chromalveolate antiparasitics (P01)

Alveo-
late

Apicom-
plexa

Conoidasida/
(Coccidiostats)

Cryptosporidiosis	thiazolide (nitazoxanide)

Isosporiasis	trimethoprim/sulfamethoxazole^#

Toxoplasmosis	pyrimethamine sulfadiazine

Aconoidasida

Malaria

Individual
agents

Hemozoin
inhibitors

aminoquinolines	(4-): amodiaquine^# chloroquine^# Tafenoquine (8-): primaquine^# pamaquine

4-methanolquinolines	mefloquine^# quinine^# quinidine

Other	lumefantrine combined with artemether halofantrine

Antifolates

DHFR inhibitors (antifols)	pyrimethamine proguanil^# chlorproguanil biguanides

Sulfonamides	sulfadoxine sulfamethoxypyrazine

Coformulation	sulfadoxine/pyrimethamine (SP)^#

Sesquiterpene
lactones

Other

Combi-
nations

Fixed-dose (coformulated) ACTs	artemether/lumefantrine^# artesunate/amodiaquine (ASAQ) artesunate/mefloquine (ASMQ) dihydroartemisinin/piperaquine artesunate/pyronaridine

Other combinations (not co-formulated)	artesunate/SP artesunate/mefloquine quinine/tetracycline quinine/doxycycline quinine/clindamycin

Babesiosis

clindamycin

Cilio-
phora

Balantidiasis: Tetracycline

Hetero-
kont

Blastocystosis: Metronidazole

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.